ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
July 07, 2021Soleno today provided an update following a recent interaction with the U.S. Food and Drug Administration (FDA) regarding the development of once-daily DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi Syndrome (PWS). -
Soleno's drug misses key goal in Prader-Willi trial
June 10, 2020Soleno Therapeutics has unveiled new data showing that its diazoxide choline controlled release (DCCR) tablets failed to reduce hyperphagia – or an abnormal desire for food – in patients with Prader-Willi syndrome.
Pharma Sources Insight January 2025
